Showing results (731-740 of 928) with videos related to

Sort By:
Pageof 93
The Lancet. Diabetes & Endocrinology|April 4, 2022
Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trialPetr Ostadal, Philippe Gabriel Steg, Yann Poulouin, et al.
The Lancet. Diabetes & Endocrinology|December 4, 2023
Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses
The Lancet. Diabetes & Endocrinology|December 7, 2023
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
The Lancet. Diabetes & Endocrinology|September 4, 2023
Maternal type 1 diabetes and relative protection against offspring transmissionLowri A Allen, Peter N Taylor, Kathleen M Gillespie, et al.
The Lancet. Diabetes & Endocrinology|September 11, 2023
The optimal healthy ranges of thyroid function defined by the risk of cardiovascular disease and mortality: systematic review and individual participant data meta-analysisYanning Xu, Arash Derakhshan, Ola Hysaj, et al.
The Lancet. Diabetes & Endocrinology|August 7, 2023
National UK guidelines for the management of paediatric craniopharyngiomaHoong-Wei Gan, Paul Morillon, Assunta Albanese, et al.
The Lancet. Diabetes & Endocrinology|October 7, 2023
Precision medicine for cardiometabolic disease: a framework for clinical translationPaul W Franks, William T Cefalu, John Dennis, et al.
The Lancet. Diabetes & Endocrinology|July 24, 2023
Lipoprotein(a) and carotid intima-media thickness in children with familial hypercholesterolaemia in the Netherlands: a 20-year follow-up studyLotte M de Boer, Albert Wiegman, Jeffrey Kroon, et al.
The Lancet. Diabetes & Endocrinology|July 10, 2023
Diagnostic challenges in cyclic Cushing's syndrome: a systematic reviewElisabeth Nowak, Frederick Vogel, Adriana Albani, et al.
The Lancet. Diabetes & Endocrinology|December 22, 2019
Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort studyHiddo J L Heerspink, Avraham Karasik, Marcus Thuresson, et al.
Pageof 93